id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-344302-p0v6sl9x	Gubitosa, James C	COVID-19-Associated Acute Limb Ischemia in a Patient on Therapeutic Anticoagulation	2020-09-25		.txt	text/plain	3092	178	41	Therapeutic anticoagulation was empirically initiated with subcutaneous enoxaparin (1 mg/kg twice daily) given the hypercoagulable state observed in many COVID-19 patients with elevated D-dimer. The risk of thromboembolic events and the sheer magnitude of COVID-19-associated admissions have prompted many hospitals to establish novel protocols with which these individuals are provided anticoagulation at increased or even therapeutic doses compared to the more common prophylactic dose. A study of 449 COVID-19 patients demonstrated a statistically significant decrease in mortality (40.0% experimental, 64.2% control) in those receiving prophylactic doses of heparin and enoxaparin [14] . Given the cited relative deficiency of ATIII in CAC and nephrotic syndrome, one can hypothesize that an acute arterial thrombosis may have been avoided if this patient was started on an argatroban infusion from the beginning of his hospital course, which would have provided therapeutic anticoagulation independent of ATIII levels. COVID-19 associated acute limb ischemia in a patient on therapeutic anticoagulation: a case and literature review	./cache/cord-344302-p0v6sl9x.txt	./txt/cord-344302-p0v6sl9x.txt